Ask about this productRelated genes to: CDK6 antibody
- Gene:
- CDK6 NIH gene
- Name:
- cyclin dependent kinase 6
- Previous symbol:
- -
- Synonyms:
- PLSTIRE
- Chromosome:
- 7q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-02-14
- Date modifiied:
- 2019-04-23
Related products to: CDK6 antibody
Related articles to: CDK6 antibody
- Analysis of runs of homozygosity (ROH) in commercial breed genomes is important for accurately assessing the population inbreeding status and exploring homozygous regions related to economic traits formed by selection pressure. The Danish Large White (LW) pig is a commercially important breed renowned for its superior growth efficiency and reproductive performance. In the present study, we identified ROH segments of Danish LW pigs based on 43 individual whole-genome resequencing data. We then calculated the inbreeding coefficient and screened candidate genes with important economic traits from the ROH islands. A total of 9446 ROH segments were identified in the LW pig population. Each LW pig carried 219.67 ROH. Most ROH were , and the average genomic inbreeding coefficient ( ) in LW pigs was 0.24. However, the proportion of ROH ( ) in LW pigs has reached 10 %, indicating selection pressure or inbreeding in recent times. Candidate genes related to reproductive traits (, , , , , , and ), and growth and development traits (, , , , , , , , , , and ) were identified in the genomic ROH islands of LW pigs. In conclusion, the present study provides further assessment of genetic diversity and inbreeding in the Danish LW pig population. In addition, our results provide useful insights into the functions of ROH on a hereditary basis and the role that ROH play in controlling the excellent characteristics of Danish LW pigs. - Source: PubMed
Publication date: 2026/01/12
Ding WeiminWu XudongBu YuZhang WeiWang YuanlangDing YueyunZheng XianruiZhang XiaodongYin Zongjun - We conducted this study to evaluate the impact of serum inflammatory markers and histopathological features on prognosis in metastatic hormone receptor positive breast cancer patients treated with first line CDK4/6i (cyclin-dependent kinase inhibitors). - Source: PubMed
Bulut NiluferKapagan TanjuOzmen AykutErdem Gokmen Umut - Integrin beta 4 (ITGB4) has been implicated in breast cancer progression, yet its clinical utility as a biomarker remains unclear due to inconsistent findings across studies. This discrepancy may stem from the failure to distinguish between RNA and protein levels. - Source: PubMed
Zhu Zhi-MinHu LeiMa Yan-WenZhu Qiong-Ni - Dysregulation of cyclin-dependent kinases (CDKs) drives uncontrolled cell cycle progression in several malignancies, making CDK4 and CDK6 appealing therapeutic targets. This paper details the rational design, synthesis, and thorough assessment of fifteen new pyrazolo[1,5-]pyrimidine derivatives (19a-o) as cyclin-dependent kinase inhibitors. Structure-activity relationship research identified compound 19i as the primary candidate, exhibiting enhanced antiproliferative efficacy against HCT-116 colorectal cancer cells with an IC of 1.02 μM, slightly higher than that of doxorubicin (IC, 1.08 μM). Mechanistic investigations demonstrated that 19i generates significant G0/G1 phase cell cycle arrest and substantial apoptotic cell death, with total apoptosis reaching 47.76% of the treated cells. ELISA analysis verified the activation of p53-dependent intrinsic apoptosis, evidenced by a 6.90-fold increase in p53, a 3.03-fold increase in Bax, a 0.39-fold decrease in Bcl-2, and a 9.56-fold increase in caspase-3 activity. Biochemical kinase tests revealed significant suppression of CDK4 (IC 0.087 μM) and CDK6 (IC 0.114 μM). Molecular docking revealed essential binding interactions, including hydrogen bonds with Lys35 and Val101, aromatic π-π stacking, and a new halogen bond with Glu94. Molecular dynamics simulations validated prolonged protein conformational stability and efficient target engagement. These findings collectively designate the pyrazolo[1,5-]pyrimidine scaffold as a viable framework for CDK-targeted anticancer therapies. - Source: PubMed
Publication date: 2026/04/20
Binjubair Faizah AElkotamy Mahmoud SMattar Amr AAlmutairy Bjad KAl-Rashood Sara TEldesouki Mohamed MBouajila JalloulAbdel-Aziz Hatem AFakhry Mariam M - - Source: PubMed
Publication date: 2026/04/16
Zhong PeilinLi WenboFeng MeiGuo AihuaWang LinhuaWu Zhongjun